-
-
Recent Posts
- Coronavirus today and the SCI community tomorrow
- Stroke Drug Boosts Stem Cell Therapy For Spinal Cord Injury In Rats
- An integrated in silico pipeline identifies a novel TF combination that promotes enhanced CST growth following injury
- Spike timing-dependent plasticity in the adult rat with chronic cervical spinal cord contusion
- Effect of PTEN antagonist peptide on the functional motor recovery in rat
- GDF10 promotes axonal regeneration and functional recovery: A novel gene therapy strategy for spinal cord injury
- GTX Medical and NeuroRecovery Technologies to merge
- Candidate Therapy From Quebec for Chronic SCI Being Developed in Parallel by Academics and Companies in Switzerland and the Netherlands
- Moving beyond the glial scar for spinal cord repair
- The Struggle to Make CNS Axons Regenerate: Why Has It Been so Difficult?
- The potential of electric field for promoting neurite guidance in spinal cord injury regeneration strategies
- Extraction and selective activation of muscle synergies through spinal stimulation for SCI
- Early limb unloading elicits long-term motor deficits involving motorneuron hyperexcitability associated with persistent alterations in glutamatergic synaptic plasticity in spinal cord injury
- The effects of a pro-angiogenic, RGD-functionalized, nanofiber composite biomaterial on mesenchymal stem cell-mediated repair of the injured spinal cord
- From wheelchair to walking after spinal cord injury
Follow on Twitter
My TweetsSpinal Cord Injury Research and Science at Facebook
Categories
Archives
Tag Archives: Dr. Ed Wirth
Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1
Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side FREMONT, Calif., June 13, 2017 /PRNewswire/ –Asterias Biotherapeutics, Inc. (NYSE MKT: AST), … Continue reading
Early Phase Clinical Trials of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (AST-OPC1) in Patients with Subacute SCI
Extensive preclinical testing of AST-OPC1 (formerly GRNOPC1) in animal models of traumatic SCI demonstrated that these cells survive, migrate throughout the injury site, and improve locomotor function. Therefore, a phase 1 clinical trial was initiated to assess the safety of … Continue reading
Posted in Regenerative Medicine, spinal cord injury research, Stem Cell Research
Tagged Asterias Biotherapeutics, Dr. Ed Wirth
Comments Off on Early Phase Clinical Trials of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (AST-OPC1) in Patients with Subacute SCI
Cell-Based Therapies for SCI: Lessons Learned in Planning and Conducting Two Phase 1 Safety Trials Over the Past 18 Years
Ed Wirth, MD, PhD Spinal Cord Injury Clinical Scientist
Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, spinal cord injury research, Stem Cell Research
Tagged chronic spinal cord injury, clinical trials, clinical trials spinal cord injury, Dr. Ed Wirth, embryonic stem cells, paralysis, regeneration, RIRC, Roman Reed, stem cell biology, stem cells
Comments Off on Cell-Based Therapies for SCI: Lessons Learned in Planning and Conducting Two Phase 1 Safety Trials Over the Past 18 Years
SPINAL CORD INJURY RESEARCH AND SCIENCE 